Ask Me Anything: Body-On-A-Chip Michael Shuler, PhD was featured on Technology Network’s Ask Me Anything: Body-On-A-Chip webinar and answered questions from a live audience. January 31, 2025: Hosted by Technology Networks, Hesperos President Michael Shuler, PhD, … Read More
ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.
FOR IMMEDIATE RELEASE ORLANDO, FL – October 24, 2024 – Hesperos, a leader in human-on-a-chip technology, has announced a breakthrough with the development of a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. Published … Read More
Hesperos Appoints L. Florin as CEO “I am excited to join Hesperos during this period of explosive growth […and] lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients … Read More
PRESS RELEASE: Hesperos announces its Human-on-a-Chip® technology supported Dianthus Therapeutics’ FDA submission for a Phase II trial of DNTH103 for generalized myasthenia gravis.
ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.
The NIH has awarded Hesperos Inc. a $2 million dollar research grant to develop an advanced, animal free platform to test the potency of Botulinum Toxin (BoT).